Abbott loses president and restructures top management
This article was originally published in Clinica
Abbott Laboratories is setting up a new management structure to tie in with the retirement of its president and chief operating officer, Robert Parkinson, after less than two years in the job. The reorganisation is part of a long-term plan to provide greater strategic and scientific focus across the company's three divisions, Abbott said. Shares in the company rose 4% to $41.4 on the news.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.